Glenmark Pharmaceuticals, a global pharmaceutical company, began a new randomized, open-label study in 158 hospitalized patients to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment. Favipiravir is an oral antiviral drug, approved in Japan since 2014, that inhibits viral replication. Umifenovir is another oral antiviral drug licensed for treatment and prophylaxis of influenza A and B infections in Russia and China. Umifenovir impede...